TABLE 7.

Immunotherapy mPFS or mOS and response probability based on different tumor mutation burden (TMB) thresholds with measurement errors for non-small-cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), bladder, renal cell carcinoma (RCC), and melanoma. p values are reported by log-rank test and the two-sided Mann–Whitney U test.

Case	Threshold	mPFS or mOS (months) for TMB_L	mPFS or mOS for (months) TMB_H	p-value	Response Prob for TMB_L (%)	Response Prob for TMB_H (%)	p-value
NSCLC	Joint model	2.03	4.33	0.022	9.375	24.39	0.100
	Median	2.13	4.33	0.046	11.11	24.31	0.145
	Top third	2.17	4.43	0.023	14.12	22.95	0.171
	75th	2.17	4.43	0.010	16.55	20.00	0.522
NPC	Joint model	1.77	2.57	0.543	6.25	18.75	0.137
	Median	1.77	2.57	0.543	6.25	18.75	0.137
	Top third	1.93	2.57	0.970	9.33	16.98	0.200
	75th	1.93	2.57	0.927	10.57	15.94	0.282
NSCLC_240	Joint model	2.9	4.2	0.016	13.39	26.56	0.011
	Median	3.1	3.77	0.264	17.5	23.33	0.140
	Top third	3.07	4.17	0.061	17.5	24.5	0.094
	75th	3.07	4.27	0.013	17.61	25.38	0.023
Mel_64	Joint model	18.51	inf	0.204	16.13	33.33	0.12
	Median	18.51	inf	0.259	18.75	31.25	0.257
	Top third	31.2	inf	0.297	22.67	28.30	0.472
	75th	32.4	inf	0.262	23.58	27.54	0.546
Mel_105	Joint model	2.7	3.3	0.019	4.65	24.19	0.007
	Median	2.8	3.27	0.835	15.38	16.98	0.829
	Top third	2.8	3.27	0.693	15.57	17.05	0.777
	75th	2.8	3.27	0.584	15.5	17.39	0.662